List of Excipients in Branded Drug BRISDELLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sebela Pharmaceuticals Inc	BRISDELLE	paroxetine	54766-907	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
Sebela Pharmaceuticals Inc	BRISDELLE	paroxetine	54766-907	FD&C RED NO. 3
Sebela Pharmaceuticals Inc	BRISDELLE	paroxetine	54766-907	FD&C RED NO. 40
Sebela Pharmaceuticals Inc	BRISDELLE	paroxetine	54766-907	FD&C YELLOW NO. 6
Sebela Pharmaceuticals Inc	BRISDELLE	paroxetine	54766-907	FERROSOFERRIC OXIDE
Sebela Pharmaceuticals Inc	BRISDELLE	paroxetine	54766-907	GELATIN
Sebela Pharmaceuticals Inc	BRISDELLE	paroxetine	54766-907	MAGNESIUM STEARATE

Brisdelle Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

Brisdelle is a low-dose, nonhormonal paroxetine mesylate capsule approved for moderate-to-severe vasomotor symptoms associated with menopause. Its commercial opportunity is driven less by active-ingredient novelty than by formulation reliability, capsule supply, generic substitutability, manufacturing scale, and differentiation from newer nonhormonal therapies such as fezolinetant.

What is Brisdelle and how is it formulated?

Brisdelle contains paroxetine mesylate equivalent to 7.5 mg of paroxetine in an oral capsule. The product is administered once daily and is approved specifically for menopausal vasomotor symptoms, not for depression, panic disorder, or other psychiatric indications.[1]

The low strength creates formulation requirements that differ from conventional paroxetine products.

Attribute	Brisdelle
Active ingredient	Paroxetine mesylate
Paroxetine equivalent	7.5 mg
Dosage form	Immediate-release hard gelatin capsule
Route	Oral
FDA application	NDA 204516
Approved indication	Moderate-to-severe menopausal vasomotor symptoms
Administration	Once daily
Hormonal content	None
Primary formulation challenge	Uniform distribution of a low active load

The marketed capsule contains inactive ingredients including microcrystalline cellulose, povidone, magnesium stearate, colloidal silicon dioxide, sodium lauryl sulfate, talc, titanium dioxide and capsule-shell components. Exact excipient grades and manufacturing parameters are commercially important because they influence blend uniformity, dissolution, capsule filling and stability.[1]

What excipients are protected or commercially important in Brisdelle?

Brisdelle’s public labeling identifies the excipients but does not disclose the full manufacturing process, supplier grades, particle-size specifications or critical process parameters. Those undisclosed parameters may provide more practical protection than the ingredient list itself.

Microcrystalline cellulose

Microcrystalline cellulose is likely to provide bulk, flow and compressibility in a formulation containing only 7.5 mg of active ingredient. Its commercial importance is high because the excipient controls powder handling and content uniformity.

Potential supplier opportunities include:

• Low-moisture grades for improved stability.
• Engineered particle-size distributions for better flow.
• Direct-blend grades that reduce segregation.
• Alternative cellulose grades that maintain dissolution and fill-weight control.

A change in cellulose grade may appear minor but can alter powder density, blend homogeneity and capsule-filling performance. Generic manufacturers would need to demonstrate that the change does not affect pharmaceutical equivalence or bioequivalence.

Povidone

Povidone can function as a binder, wetting aid or dispersion-support excipient. In a low-dose capsule, its value is linked to maintaining uniform distribution of paroxetine mesylate throughout the blend.

Commercial opportunities include controlled-viscosity grades, low-peroxide grades and grades optimized for dry blending. Peroxide control matters because oxidative impurities can affect active-ingredient stability and impurity profiles.

Colloidal silicon dioxide

Colloidal silicon dioxide improves flow and reduces cohesion. It is especially relevant where a low-dose drug substance is blended with a relatively large excipient mass.

Potential improvements include:

• Better powder flow during high-speed encapsulation.
• Reduced weight variability.
• Lower dust generation.
• More consistent blending across commercial-scale equipment.

The excipient itself is generally not a strong standalone barrier. The value lies in the selected grade, concentration and process integration.

Magnesium stearate

Magnesium stearate reduces friction during manufacturing. Excessive levels or prolonged lubrication can impair dissolution or create hydrophobic coating effects around particles.

A supplier or formulation developer could pursue lower-lubricant systems, shorter blending cycles or alternative lubricants. Any change would require dissolution and bioequivalence evaluation because paroxetine release may be sensitive to powder wetting and hydrophobicity.

Sodium lauryl sulfate

Sodium lauryl sulfate can improve wetting and dispersion. Its presence creates a potential reformulation opportunity because some manufacturers seek to reduce surfactant exposure in oral products.

Possible strategies include:

• Replacing sodium lauryl sulfate with a different wetting agent.
• Reducing its concentration through particle engineering.
• Using a paroxetine mesylate grade with improved wettability.
• Adopting a co-processed excipient system.

The commercial case depends on whether the reformulation improves tolerability, stability, manufacturability or supply security without changing dissolution behavior.

Capsule shell

Brisdelle uses a hard capsule shell. Capsule-shell selection affects moisture transfer, mechanical strength, appearance, swallowability and consumer acceptance.

Potential opportunities include:

• Hydroxypropyl methylcellulose capsules for vegetarian positioning.
• Lower-moisture gelatin systems.
• Improved shell opacity and color consistency.
• Tamper-evident or serialization-compatible packaging.
• Capsule shells optimized for high-speed filling.

A shell substitution is not automatically a low-risk change. The manufacturer must assess dissolution, moisture sensitivity, shell brittleness, stability and bioequivalence implications.

What formulation patents protect Brisdelle?

Brisdelle’s principal commercial protection has historically centered on the use of low-dose paroxetine for menopausal vasomotor symptoms and the approved product configuration, rather than on a technically complex delivery platform.

The FDA Orange Book is the controlling public source for patents and regulatory exclusivity associated with NDA 204516.[2] The product label alone does not establish the current patent list, expiration dates or whether any listed patent remains enforceable against a particular ANDA applicant.

The most important protection categories are:

1. Low-dose paroxetine for menopausal vasomotor symptoms.
2. Method-of-use claims covering treatment of hot flashes or vasomotor symptoms.
3. Product claims covering paroxetine mesylate at the approved strength.
4. Formulation claims covering capsule composition or dissolution characteristics.
5. Regulatory exclusivity associated with the original approval.

Method-of-use claims can remain commercially relevant even when composition claims have expired. Their value depends on the exact claim language, the approved labeling, induced-infringement risk and the ANDA applicant’s Paragraph IV certification.

A serious freedom-to-operate review should compare the current Orange Book listing with:

• The approved label.
• Patent term adjustment.
• Patent-term extension.
• Terminal disclaimers.
• Reissued or continuation patents.
• Paragraph IV notices.
• Litigation settlements.
• Any covenant not to sue or license agreement.

When does Brisdelle lose exclusivity?

Brisdelle’s exclusivity position depends on three separate timelines:

Exclusivity category	Commercial significance
FDA regulatory exclusivity	Controls when an ANDA or certain 505(b)(2) applications may be approved
Orange Book patents	Can delay or complicate generic approval
Trade secrets and know-how	Can preserve manufacturing advantages after formal exclusivity ends

Brisdelle received FDA approval in 2013.[1] Regulatory exclusivity associated with an original small-molecule approval is time-limited. Patent protection must be assessed independently through the current Orange Book record and the underlying patent documents.[2]

The commercial implication is direct: once regulatory barriers and enforceable patent barriers are removed, an ANDA applicant can pursue a therapeutically equivalent generic paroxetine mesylate 7.5 mg capsule. At that point, excipient differentiation becomes more valuable for authorized-generic supply, manufacturing contracts, brand repositioning and lifecycle management than for blocking ordinary generic entry.

What Paragraph IV risks exist for Brisdelle?

A Paragraph IV challenge would typically target patents listed for the product in the Orange Book. The applicant would assert that the listed patent is invalid, unenforceable or not infringed.

The principal risk areas are:

• A challenge to method-of-use claims for menopausal vasomotor symptoms.
• A non-infringement position based on a narrower generic label.
• An invalidity challenge based on obviousness or written-description grounds.
• A product-by-process or formulation distinction.
• A carve-out of patented use from the generic label.

For Brisdelle, a generic applicant may have a strong commercial incentive to use the same active ingredient and dosage strength because paroxetine is widely available and the product is an immediate-release oral capsule. The technical barrier is likely lower than for modified-release, injectable or biologic products.

The brand owner’s response would normally include patent litigation, a request for a 30-month stay where legally available, settlement negotiations, or an authorized-generic strategy. The business value of litigation depends on the remaining patent term and the size of the menopause market.

What commercial opportunities exist for Brisdelle excipients?

Second-source excipient supply

The clearest opportunity is qualified dual sourcing. Suppliers can target:

• Microcrystalline cellulose.
• Povidone.
• Colloidal silicon dioxide.
• Magnesium stearate.
• Sodium lauryl sulfate.
• Gelatin or HPMC capsule shells.

A second-source supplier must match functional performance, not merely compendial identity. The required package includes particle-size data, bulk and tapped density, moisture profile, microbial limits, elemental impurities, residual solvents, peroxide levels and lot-to-lot variability.

Co-processed excipients

A co-processed filler-flow aid system could reduce segregation and improve encapsulation efficiency. The commercial proposition would be strongest if it reduces:

• Blend sampling failures.
• Capsule weight variability.
• Manufacturing scrap.
• Dust and operator exposure.
• Scale-up time.

The primary regulatory risk is that a co-processed material may change dissolution or bioequivalence. A supplier should therefore support comparative dissolution across multiple pH conditions and provide robust extractables, leachables and stability data where relevant.

Capsule-shell substitution

HPMC capsule shells could support vegetarian positioning and reduce dependence on gelatin supply. The opportunity is commercially attractive but requires a full comparability program covering:

• Shell moisture.
• Disintegration.
• Dissolution.
• Mechanical strength.
• Storage under accelerated conditions.
• Compatibility with the powder blend.

Excipient-driven lifecycle management

A reformulated Brisdelle product could target improved swallowability, lower surfactant content, greater stability or simplified manufacturing. Such a product would not automatically receive meaningful new patent protection. Stronger lifecycle value would require a defensible technical improvement, a differentiated clinical or tolerability profile, and an appropriate FDA pathway.

How does Brisdelle compare with competing menopause therapies?

Product or category	Active ingredient	FDA status for vasomotor symptoms	Formulation and commercial implication
Brisdelle	Paroxetine mesylate 7.5 mg	Approved	Low-dose capsule; generic substitution risk
Veozah	Fezolinetant	Approved	Newer nonhormonal oral product; greater active-ingredient and regulatory differentiation
Hormone therapy	Estrogen with or without progestogen	Approved for selected indications	Strong clinical efficacy but hormonal safety and labeling constraints
SSRIs/SNRIs	Various	Several used off-label	Low-cost competition, but not all have the Brisdelle indication
Gabapentin	Gabapentin	Off-label for vasomotor symptoms	Generic, low-cost alternative
Oxybutynin	Oxybutynin	Off-label	Anticholinergic safety and tolerability considerations

Fezolinetant creates the most direct branded nonhormonal competitive pressure because it has a specific FDA indication for moderate-to-severe vasomotor symptoms. Brisdelle retains potential advantages in familiarity, low-dose oral administration and generic supply economics, while paroxetine-related contraindications and drug-interaction concerns remain relevant.[1,3]

What is the FDA and Orange Book status of Brisdelle?

Brisdelle is an FDA-approved prescription drug under NDA 204516.[1] It is a small-molecule product, so biosimilar regulation does not apply. Future competition would arise through ANDAs or, in some circumstances, 505(b)(2) applications rather than biosimilar applications.

The Orange Book should be used to confirm:

• Current listed patents.
• Patent-use codes.
• Applicant holder.
• Exclusivity status.
• Therapeutic-equivalence ratings for approved generics.
• Any litigation-related approval restrictions.[2]

FDA approval of a generic would not necessarily mean immediate commercial launch. Launch timing can be affected by patent settlements, first-filer exclusivity, manufacturing readiness, controlled distribution terms and commercial agreements.

What manufacturing and IP barriers remain after patent expiry?

The main post-expiry barriers are operational rather than scientific:

• Low-dose content uniformity.
• Powder segregation.
• API particle-size control.
• Moisture management.
• Capsule-shell compatibility.
• Supplier qualification.
• Stability throughout the proposed shelf life.
• Commercial-scale encapsulation yield.
• FDA inspection readiness.

Trade secrets covering blend order, screen size, lubrication time, environmental controls and in-process sampling can create manufacturing advantages. These rights do not prevent generic entry, but they can reduce the cost and time required to produce a reliable product.

How strong is the Brisdelle patent estate?

Brisdelle’s patent estate is likely more vulnerable to generic competition than estates built around complex delivery technologies, biologics or difficult-to-reproduce dosage forms. The product uses a conventional immediate-release capsule and an established small-molecule active ingredient.

Its strongest potential protection lies in narrow method-of-use claims and any surviving Orange Book-listed patents. Its weaker areas are conventional excipient composition, routine capsule technology and the broad availability of paroxetine manufacturing capability.

Commercial strength therefore depends on the remaining enforceable patent term, the scope of any use code, the brand’s prescriber base, payer treatment and the cost advantage of a generic entrant.

Key Takeaways

• Brisdelle is a 7.5 mg paroxetine mesylate capsule approved for menopausal vasomotor symptoms.
• The principal excipient opportunity is functional equivalence, not simple ingredient substitution.
• Microcrystalline cellulose, povidone, flow aids, lubricants and capsule shells are the most commercially relevant excipient categories.
• HPMC capsule shells and lower-surfactant formulations offer potential lifecycle strategies.
• Brisdelle is a small molecule, so biosimilar risk does not apply; ANDA-based generic competition is the relevant pathway.
• The FDA Orange Book must be used to confirm live patents, use codes, exclusivity and generic approval barriers.
• A conventional immediate-release capsule creates a lower technical entry barrier than modified-release products or biologics.
• The strongest post-patent commercial defenses are supply reliability, manufacturing yield, authorized-generic strategy and brand positioning against newer nonhormonal therapies.

FAQs

Can Brisdelle be reformulated without a new clinical trial?

Some excipient changes may be handled through an approved-product supplement or an ANDA pathway if pharmaceutical equivalence, dissolution and bioequivalence requirements are met. A materially different formulation may require a more extensive FDA submission.

Is paroxetine 7.5 mg the same as ordinary generic paroxetine?

No. Brisdelle contains the same pharmacologically active ingredient family but is approved at a specific 7.5 mg strength for menopausal vasomotor symptoms. Generic paroxetine products approved for psychiatric indications are not automatically substitutable for Brisdelle.

Could a generic use different excipients?

Yes, subject to FDA requirements. The generic must demonstrate pharmaceutical equivalence and bioequivalence, and its inactive ingredients must be acceptable for the dosage form and route of administration.

Does Brisdelle qualify for biosimilar competition?

No. Brisdelle contains a chemically synthesized small molecule. Competition would generally proceed through an ANDA or another small-molecule regulatory pathway, not a biosimilar application.

What is the best excipient investment angle for Brisdelle?

The strongest near-term opportunity is a qualified second-source or co-processed excipient system that improves blend uniformity, flow, moisture control or capsule-filling yield without materially changing dissolution or bioavailability.

References

1. U.S. Food and Drug Administration. (2023). Brisdelle (paroxetine mesylate) capsules, prescribing information.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. U.S. Food and Drug Administration. (2023). Veozah (fezolinetant) prescribing information.